This Clinical Evidence Synopsis summarizes a Cochrane review of clinical trials that characterize the diagnostic accuracy of blood carcinoembryonic antigen for detecting recurrent colorectal cancer.
This Recommendation Statement from the US Preventive Services Task Force recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years (A recommendation) and recommends that for adults aged 76 to 85 years the decision to screen for colorectal cancer should be an individual one that takes into account the patient’s overall health and prior screening history (C recommendation).
This systematic review to support the 2016 update of the US Preventive Services Task Force Recommendation Statement on screening for colorectal cancer summarizes published evidence about the effectiveness of routine screening, accuracy of screening tests and strategies, and potential screening harms.
This Viewpoint discusses the basis for the FDA’s 2016 approval of the blood-based septin 9 gene (SEPT9) assay as a screening test for colon cancer and concerns about its accuracy and use in clinical practice.
This Viewpoint examines differences in the funding, quality, and reporting standards for breast, colorectal, and cervical cancer screening.
This study assesses associations between measures of aggressive end-of-life care and bereaved family members’ perceptions of the quality of care in Medicare beneficiaries who died of lung or colorectal cancer between 2003 and 2011.
This study uses data from the Surveillance, Epidemiology, and End Results database to examine the association between access to paid sick leave and job retention and personal financial burden among patients with colorectal cancer.
This From The JAMA Network article discusses the treatment decision process for young adults with colorectal cancer in relation to a nationwide cohort study of treatments and prognoses reported in JAMA Surgery.
Using colon cancer registry data, these investigators found that in women with a mismatch repair gene mutation, hormonal factors such as age at menarche, parity, and use of hormonal contraceptives were associated with a lower risk of endometrial cancer.
This simulation study uses Kaiser Permanente patient data to estimate benefits, complications, and costs of colorectal cancer screening stratified by adenoma detection rate and age at initiation.
This genome-wide association study identifies single-nucleotide polymorphisms that influence the association between use of aspirin, nonsteroidal anti-inflammatory drugs, or both and colorectal cancer.
The FDA has approved a stool DNA test to screen average-risk adults ≥50 years old for colorectal cancer.
In a population-based randomized clinical trial of 98 792 individuals in Norway, Holme and colleagues compare the effectiveness of flexible sigmoidoscopy vs the combination of flexible sigmoidoscopy and fecal occult blood testing, vs no screening on colorectal cancer incidence and mortality.
Primrose and coauthors conducted a randomized clinical trial among 1202 patients at 39 hospitals in England to assess the effectiveness of blood measurement of carcinoembryonic antigen (CEA) and computed tomography (CT) as follow-up to detect recurrent colorectal cancer treatable with curative intent.